Company intelligence / Profile preview

Hexin Pharmaceutical

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

177Lu-HX02 injection (radiotherapeutic, targeting integrin αvβ3/CD13) gained clinical approval in China (IND clearance), following successful 68Ga diagnostic product approval in 2022. Clinical data is pending; development milestones include dual diagnostic and therapeutic radiopharmaceuticals for solid tumors[2].

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalSmall molecule
Industry: Biotech

Partnerships

Mitro Biotech (CRDMO partner for radiopharmaceutical R&D and IND support)[2]

Beyond the preview

Go deeper on Hexin Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hexin Pharmaceutical.

Explore the full profile